Retro-transduction by virus pseudotyped with glycoprotein of vesicular stomatitis virus

Virology

Volumn 362, Issue 1, 2007, Pages 131-138

  Ohishi, Masahisa ^a   Shioda, Tatsuo ^a   Sakuragi, Jun ichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

HIV 1; Pseudotyping; Retro transduction; Viral vector; VSV G

Indexed keywords

GLYCOPROTEIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ARTICLE; CELL CULTURE; DNA INTEGRATION; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROGENY; PSEUDOTYPING; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS INFECTIVITY;

CELL LINE; DNA, VIRAL; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HIV CORE PROTEIN P24; HIV-1; HUMANS; MEMBRANE GLYCOPROTEINS; TIME FACTORS; TRANSDUCTION, GENETIC; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS INTEGRATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 34247250802     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.12.030     Document Type: Article

References (20)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., and Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59 (1986) 284-291
2. Aldovini A., and Walker B.D. Techniques in HIV Research (1990), Stockton Press, New York
3. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., and Struhl K. (Eds). Short Protocols in Molecular Biology. 3rd edition (1995), John Wiley and Sons Inc., Hoboken, NJ
4. Brussel A., and Sonigo P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J. Virol. 77 18 (2003) 10119-10124
5. Burns J.C., Friedmann T., Driever W., Burrascano M., and Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90 17 (1993) 8033-8037
6. Fredericksen B.L., and Whitt M.A. Vesicular stomatitis virus glycoprotein mutations that affect membrane fusion activity and abolish virus infectivity. J. Virol. 69 3 (1995) 1435-1443
7. Ikeda T., Nishitsuji H., Zhou X., Nara N., Ohashi T., Kannagi M., and Masuda T. Evaluation of the functional involvement of human immunodeficiency virus type 1 integrase in nuclear import of viral cDNA during acute infection. J. Virol. 78 21 (2004) 11563-11573
8. Julias J.G., Ferris A.L., Boyer P.L., and Hughes S.H. Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J. Virol. 75 14 (2001) 6537-6546
9. Kallio P.J., Okamoto K., O'Brien S., Carrero P., Makino Y., Tanaka H., and Poellinger L. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J. 17 22 (1998) 6573-6586
10. Liu M.L., Winther B.L., and Kay M.A. Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-Moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer. J. Virol. 70 4 (1996) 2497-2502
11. Markowitz M., Mo H., Kempf D.J., Norbeck D.W., Bhat T.N., Erickson J.W., and Ho D.D. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69 2 (1995) 701-706
12. Mastromarino P., Conti C., Goldoni P., Hauttecoeur B., and Orsi N. Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J. Gen. Virol. 68 Pt. 9 (1987) 2359-2369
13. McBride M.S., and Panganiban A.T. The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures. J. Virol. 70 5 (1996) 2963-2973
14. McClure M.O., Sattentau Q.J., Beverley P.C., Hearn J.P., Fitzgerald A.K., Zuckerman A.J., and Weiss R.A. HIV infection of primate lymphocytes and conservation of the CD4 receptor. Nature 330 6147 (1987) 487-489
15. Mitsuya H., Weinhold K.J., Furman P.A., St Clair M.H., Lehrman S.N., Gallo R.C., Bolognesi D., Barry D.W., and Broder S. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 82 20 (1985) 7096-7100
16. Miyoshi H., Blomer U., Takahashi M., Gage F.H., and Verma I.M. Development of a self-inactivating lentivirus vector. J. Virol. 72 10 (1998) 8150-8157
17. Nagao T., Yoshida A., Sakurai A., Piroozmand A., Jere A., Fujita M., Uchiyama T., and Adachi A. Determination of HIV-1 infectivity by lymphocytic cell lines with integrated luciferase gene. Int. J. Mol. Med. 14 6 (2004) 1073-1076
18. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 2 (1991) 193-199
19. Shibata R., Miura T., Hayami M., Ogawa K., Sakai H., Kiyomasu T., Ishimoto A., and Adachi A. Mutational analysis of the human immunodeficiency virus type 2 (HIV-2) genome in relation to HIV-1 and simian immunodeficiency virus SIV (AGM). J. Virol. 64 2 (1990) 742-747
20. Willey R.L., Smith D.H., Lasky L.A., Theodore T.S., Earl P.L., Moss B., Capon D.J., and Martin M.A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62 1 (1988) 139-147